Survodutide (BI 456906) is a synthetic dual glucagon receptor/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike other dual agonists based on oxyntomodulin, survodutide is a glucagon analog with engineered GLP-1 activity, featuring a non-coded amino acid (1-aminocyclobutane-1-carboxylic acid) at position 2 and a C18 fatty diacid at Lys24 for albumin binding and extended half-life.
Investigational drug in Phase 3 trials (SYNCHRONIZE program). Phase 2 studied doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg administered subcutaneously once weekly with a 20-week bi-weekly dose escalation phase followed by 26-week maintenance. Not yet approved for clinical use.
Mechanisms of Action
4Benefits
4Significant weight loss
Body CompositionPhase 2 trials demonstrated up to 14.9% mean weight loss (18.7% in completers) at the 4.8 mg dose over 46 weeks.
Glycemic improvement
MetabolicReduces HbA1c in patients with type 2 diabetes, with dose-dependent improvements observed in clinical trials.
Hepatic fat reduction (MASH/NASH)
MetabolicShows promise for treating metabolic dysfunction-associated steatohepatitis through reduction of liver fat content.
Blood pressure reduction
MetabolicPost-hoc analysis showed significant blood pressure improvements in adults with obesity.
Research Studies
3This database is for educational and research purposes only. It is not medical advice. Consult a healthcare professional before using any peptide or supplement.